RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
LAKE FOREST, Ill., Oct. 13, 2016 -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, November 3, 2016 outlining the third quarter 2016 results.
In addition, the Company will host a conference call at 10:00 am EDT on the same day to discuss its third quarter 2016 financial results. The dial-in number to access the call is (844) 249-9382 in the U.S. and +1 (270) 823-1530 for international callers. The conference ID is 96008765. To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.
A webcast replay of the conference call will be available shortly following the conclusion of the call and will be available for 90 days following the call. To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.
About Akorn:
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.
Investors/Media: Stephanie Carrington ICR, Inc. (646) 277-1282 [email protected]
